产品名称 Remogliflozin - GSK 189074
产品货号 Axon 1634 CAS [329045-45-6] MF C23H34N2O7MW 450.53 Purity: 99% Soluble in water and DMSO Description Remogliflozin inhibits the sodium-glucose transport (SGLT2) proteins, which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. Its prodrug is Remoglifozin etabonate (GSK 189075), investigated as a treatment of anti diabetes type II References Certificates Categories Extra info Y Fujimori et al. Remogliflozin Etabonate, in a Novel Category of Selective Low-Affinity Sodium Glucose Cotransporter (SGLT2) Inhibitors, Exhibits Antidiabetic Efficacy in Rodent Models. J. Pharmacol. Exp. Ther. 2008, 327(1), 268-276. Certificate of Analysis Material Safety Data Sheet Diabetes & Metabolism SGLT2 Sodium-Glucose Co-transproter SGLT2 inhibitor Chemical name (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(4-(4-isopropoxybenzyl)-1-isopropyl-5-methyl-1H-pyrazol-3-yloxy)tetrahydro-2H-pyran-3,4,5-triol Parent CAS No. [329045-45-6] Order Size Unit Price Stock 5 mg €135.00 In Stock
产品价格 现货询价,电话:010-67529703
产品规格
产品品牌 axonmedchem
产品概述
产品详情

Remogliflozin - GSK 189074

Based on 15 reference(s) in Google Scholar 8 10 15

Axon 1634

CAS [329045-45-6]

MF C23H34N2O7
MW 450.53

  • Purity: 99%
  • Soluble in water and DMSO

Remogliflozin

Description

Remogliflozin inhibits the sodium-glucose transport (SGLT2) proteins, which are responsible for glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine. Its prodrug is Remoglifozin etabonate (GSK 189075), investigated as a treatment of anti diabetes type II
产品资料